search
Back to results

Validation of Next Generation Cerebral and Tissue Oximeter

Primary Purpose

Oxygen Deficiency

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Desaturation
Sponsored by
Medtronic - MITG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Oxygen Deficiency

Eligibility Criteria

18 Years - 46 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy, male or female subjects between the ages of 18 to ≤46 years;
  2. Completion of a health screening for a medical history by a licensed physician, nurse practitioner or physician assistant;
  3. Minimum weight 40kg;
  4. BMI within range 18.0 - 30.0.

Exclusion Criteria:

  1. Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) [self-reported];
  2. Prior known severe allergies to medical grade adhesive/tape (Band-Aid) [self-reported];
  3. Taking any medication other than birth control [self-reported];
  4. Is currently participating in, or has recently participated in (discontinued within 30 days prior to the hypoxia procedure for this study) in an investigational drug, device, or biologic study [self-reported];
  5. Has a negative Allen's Test to confirm non-patency of the collateral artery [clinical assessment by PI or delegate];
  6. Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure [self-reported];
  7. Is female with a positive pregnancy test [serum or urine], or is female and is unwilling to use effective birth control between the time of screening and study procedure or is breastfeeding;
  8. Has anemia [lab values specific for gender];
  9. Has a history of sickle cell trait or thalassemia [self-reported];
  10. Has an abnormal hemoglobin electrophoresis test [lab measurement];
  11. Has a positive urine cotinine test or urine drug screen or oral ethanol test [POC testing];
  12. Has a room air saturation less than 95% by pulse oximetry [measurement by PI or delegate];
  13. Has a clinically significant abnormal ECG [assessment by PI or delegate];
  14. Has a clinically significant abnormal pulmonary function test via spirometry [assessment by PI or delegate];
  15. Has a COHb greater than 3%, or MetHb greater than 2% [measured by venous blood sample co-oximetry]

Sites / Locations

  • Duke University Hospital, HPPL

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Desaturation

Arm Description

Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.

Outcomes

Primary Outcome Measures

Validated the Next Generation Oximeter
Cerebral overall mean bias (percentage saturation) defined as the average of the differences between the regional saturation (rSO2) value and (fSO2) value obtained from simultaneous arterial and jugular venous blood samples. Cerebral trending is defined as the measurement of changes in regional saturation (rSO2) under conditions of changing fSO2. Cerebral trending mean bias is the average difference between changes in rSO2 values compared against changes in fSO2. Somatic trending mean bias is defined the same as Cerebral trending mean bias except for the location of measurement on the subjects and for Somatic trending mean bias, rS02 was compared to rSO2 on a commercially-available regional oximetry monitor. The smaller value the better performance.

Secondary Outcome Measures

Full Information

First Posted
April 5, 2017
Last Updated
October 12, 2018
Sponsor
Medtronic - MITG
search

1. Study Identification

Unique Protocol Identification Number
NCT03128372
Brief Title
Validation of Next Generation Cerebral and Tissue Oximeter
Official Title
Validation of Next Generation INVOS NIRS Cerebral and Tissue Oximeter to Measure Cerebral and Somatic Tissue Oxygen Saturation in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
May 22, 2017 (Actual)
Primary Completion Date
July 19, 2017 (Actual)
Study Completion Date
July 19, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic - MITG

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a validation study of a near-infrared spectroscopy (NIRS) device designed to measure the cerebral tissue oxygen saturation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oxygen Deficiency

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Desaturation
Arm Type
Experimental
Arm Description
Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
Intervention Type
Device
Intervention Name(s)
Desaturation
Other Intervention Name(s)
Cerebral and Tissue Oximeter
Intervention Description
The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
Primary Outcome Measure Information:
Title
Validated the Next Generation Oximeter
Description
Cerebral overall mean bias (percentage saturation) defined as the average of the differences between the regional saturation (rSO2) value and (fSO2) value obtained from simultaneous arterial and jugular venous blood samples. Cerebral trending is defined as the measurement of changes in regional saturation (rSO2) under conditions of changing fSO2. Cerebral trending mean bias is the average difference between changes in rSO2 values compared against changes in fSO2. Somatic trending mean bias is defined the same as Cerebral trending mean bias except for the location of measurement on the subjects and for Somatic trending mean bias, rS02 was compared to rSO2 on a commercially-available regional oximetry monitor. The smaller value the better performance.
Time Frame
Data collected from individual participant over 4 hour timeframe.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
46 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy, male or female subjects between the ages of 18 to ≤46 years; Completion of a health screening for a medical history by a licensed physician, nurse practitioner or physician assistant; Minimum weight 40kg; BMI within range 18.0 - 30.0. Exclusion Criteria: Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) [self-reported]; Prior known severe allergies to medical grade adhesive/tape (Band-Aid) [self-reported]; Taking any medication other than birth control [self-reported]; Is currently participating in, or has recently participated in (discontinued within 30 days prior to the hypoxia procedure for this study) in an investigational drug, device, or biologic study [self-reported]; Has a negative Allen's Test to confirm non-patency of the collateral artery [clinical assessment by PI or delegate]; Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure [self-reported]; Is female with a positive pregnancy test [serum or urine], or is female and is unwilling to use effective birth control between the time of screening and study procedure or is breastfeeding; Has anemia [lab values specific for gender]; Has a history of sickle cell trait or thalassemia [self-reported]; Has an abnormal hemoglobin electrophoresis test [lab measurement]; Has a positive urine cotinine test or urine drug screen or oral ethanol test [POC testing]; Has a room air saturation less than 95% by pulse oximetry [measurement by PI or delegate]; Has a clinically significant abnormal ECG [assessment by PI or delegate]; Has a clinically significant abnormal pulmonary function test via spirometry [assessment by PI or delegate]; Has a COHb greater than 3%, or MetHb greater than 2% [measured by venous blood sample co-oximetry]
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julia Katilius
Organizational Affiliation
Medtronic
Official's Role
Study Director
Facility Information:
Facility Name
Duke University Hospital, HPPL
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Validation of Next Generation Cerebral and Tissue Oximeter

We'll reach out to this number within 24 hrs